Thalidomide treatment in advanced refractory myeloma
نویسندگان
چکیده
منابع مشابه
Thalidomide in patients with advanced multiple myeloma.
INTRODUCTION Recently, a report has suggested the efficacy and safety of thalidomide in refractory multiple myeloma. In an attempt to assess the efficacy and tolerance of thalidomide in advanced multiple myeloma (on behalf of the Intergroupe Franchophone dy Myelome (IFM)), we report the preliminary experience of the IFM with this drug. MATERIALS AND METHODS Patients with advanced multiple mye...
متن کاملSalvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
BACKGROUND AND OBJECTIVES Few therapeutic options are presently available for patients with multiple myeloma (MM) who relapse after autologous or allogeneic stem cell transplantation, or for patients who are refractory to conventional chemotherapy and not eligible for salvage high-dose therapy. Thalidomide, a glutamic acid derivative with anti-angiogenic properties, has been recently proposed a...
متن کاملAntitumor activity of thalidomide in refractory multiple myeloma.
BACKGROUND Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, in patients with refractory disease. METHODS Eighty-four previously treated patients with refractory myeloma (76 with a relapse after h...
متن کاملPulmonary hypertension related to thalidomide therapy in refractory multiple myeloma.
Thalidomide is an effective treatment both in advanced multiple myeloma (MM) and as first-line therapy in combination with dexamethasone or other cytotoxic chemotherapy [1, 2]. Two cases [3, 4] of pulmonary hypertension in the absence of thromboembolic events have been described in patients with MM during thalidomide treatment [5]. A 63-year-old woman was diagnosed in 1998 with IIA MM IgG kappa...
متن کاملThalidomide and dexamethasone combination for refractory multiple myeloma.
BACKGROUND Thalidomide is effective in approximately 30% of patients with refractory multiple myeloma. Dexamethasone is active in 25% of patients with disease resistant to alkylating agents. We investigated the combination of thalidomide with dexamethasone as salvage treatment for heavily pretreated patients with multiple myeloma, in order to assess its efficacy and toxicity. PATIENTS AND MET...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2000
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2000.2393-2.x